221 related articles for article (PubMed ID: 37978195)
61. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
Jarmalavicius S; Welte Y; Walden P
J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
[TBL] [Abstract][Full Text] [Related]
62. HLAII peptide presentation of infliximab increases when complexed with TNF.
Casasola-LaMacchia A; Seward RJ; Tourdot S; Willetts M; Kruppa G; Agostino MJ; Bergeron G; Ahyi-Amendah N; Ciarla A; Lu Z; Kim HY; Hickling TP; Neubert H
Front Immunol; 2022; 13():932252. PubMed ID: 36177046
[TBL] [Abstract][Full Text] [Related]
63. High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.
Chong C; Marino F; Pak H; Racle J; Daniel RT; Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Mol Cell Proteomics; 2018 Mar; 17(3):533-548. PubMed ID: 29242379
[TBL] [Abstract][Full Text] [Related]
64. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.
Kumari S; Wälchli S; Fallang LE; Yang W; Lund-Johansen F; Schumacher TN; Olweus J
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):403-8. PubMed ID: 24344295
[TBL] [Abstract][Full Text] [Related]
65. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
[TBL] [Abstract][Full Text] [Related]
66. New insights and approaches for analyses of immunopeptidomes.
Illing PT; Ramarathinam SH; Purcell AW
Curr Opin Immunol; 2022 Aug; 77():102216. PubMed ID: 35716458
[TBL] [Abstract][Full Text] [Related]
67. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
[TBL] [Abstract][Full Text] [Related]
68. Immunopeptidogenomics: Harnessing RNA-Seq to Illuminate the Dark Immunopeptidome.
Scull KE; Pandey K; Ramarathinam SH; Purcell AW
Mol Cell Proteomics; 2021; 20():100143. PubMed ID: 34509645
[TBL] [Abstract][Full Text] [Related]
69. New light on the HLA-DR immunopeptidomic landscape.
Egholm Bruun Jensen E; Reynisson B; Barra C; Nielsen M
J Leukoc Biol; 2024 Apr; 115(5):913-925. PubMed ID: 38214568
[TBL] [Abstract][Full Text] [Related]
70. Recent advances in immunopeptidomic-based tumor neoantigen discovery.
Meng W; Schreiber RD; Lichti CF
Adv Immunol; 2023; 160():1-36. PubMed ID: 38042584
[TBL] [Abstract][Full Text] [Related]
71. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
[TBL] [Abstract][Full Text] [Related]
72. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
73. Mass spectrometry-based antigen discovery for cancer immunotherapy.
Bassani-Sternberg M; Coukos G
Curr Opin Immunol; 2016 Aug; 41():9-17. PubMed ID: 27155075
[TBL] [Abstract][Full Text] [Related]
74. Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.
Yaciuk JC; Skaley M; Bardet W; Schafer F; Mojsilovic D; Cate S; Stewart CJ; McMurtrey C; Jackson KW; Buchli R; Olvera A; Cedeño S; Plana M; Mothe B; Brander C; West JT; Hildebrand WH
J Virol; 2014 Nov; 88(22):12992-3004. PubMed ID: 25165114
[TBL] [Abstract][Full Text] [Related]
75. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.
Caron E; Kowalewski DJ; Chiek Koh C; Sturm T; Schuster H; Aebersold R
Mol Cell Proteomics; 2015 Dec; 14(12):3105-17. PubMed ID: 26628741
[TBL] [Abstract][Full Text] [Related]
76. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
77. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types.
Gartner JJ; Parkhurst MR; Gros A; Tran E; Jafferji MS; Copeland A; Hanada KI; Zacharakis N; Lalani A; Krishna S; Sachs A; Prickett TD; Li YF; Florentin M; Kivitz S; Chatmon SC; Rosenberg SA; Robbins PF
Nat Cancer; 2021 May; 2(5):563-574. PubMed ID: 34927080
[TBL] [Abstract][Full Text] [Related]
78. MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies.
Taylor HB; Klaeger S; Clauser KR; Sarkizova S; Weingarten-Gabbay S; Graham DB; Carr SA; Abelin JG
Mol Cell Proteomics; 2021; 20():100116. PubMed ID: 34146720
[TBL] [Abstract][Full Text] [Related]
79. COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome.
Wang F; Zhang Z; Mao M; Yang Y; Xu P; Lu S
J Transl Med; 2024 Feb; 22(1):144. PubMed ID: 38336780
[TBL] [Abstract][Full Text] [Related]
80. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
